ScreenerHero
PPGNPolyPeptide Group AG
SWX · CH · Healthcare · Drug Manufacturers - Specialty & Generic · polypeptide.com
44.00CHF+0.11%Mkt Cap: 1.66B $P/E: 107.20

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceut…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.66B $
Enterprise Value1.76B $
Revenue (TTM)523.70M $
Gross Profit75.94M $
Net Income (TTM)-24.16M $
Revenue/Share16.05 USD
Last Price44.00 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.5K
CountryCH
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)107.20
P/E (Forward)30.60
PEG—
EV/EBITDA20.43
EV/Revenue3.36
P/S3.17
P/B4.57
EPS (TTM)0.41
EPS (Forward)1.44
52W Range
21.8078% of range50.10
52W High50.10 CHF
52W Low21.80 CHF
Profitability
Gross Margin16.98%
Oper. Margin9.29%
EBITDA Margin16.44%
Profit Margin-5.40%
ROE-6.22%
ROA-2.56%
Growth
Revenue Growth41.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF88.46M $
CapEx (TTM)124.29M $
FCF Margin-20.18%
FCF Yield-6.38%
Net Debt102.92M $
Net Debt/EBITDA1.20
Balance Sheet
Debt/Equity0.38
Current Ratio1.64
Quick Ratio0.76
Book Value/Sh9.621 CHF
Cash/Share1.788 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 28, 2022
Pay DateMay 2, 2022
Analyst Consensus
Rating2.5 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.39 CHF
Upside (mean)-10.5%
Target Range25.89 CHF – 44.08 CHF
CHF25.89-10.5% to meanCHF44.08
# Analysts5
Ownership
Shares Out.33.02M
Float12.97M
Insiders60.52%
Institutions15.30%
Technical
SMA 5043.44 (+1.3%)
SMA 20032.71 (+34.5%)
Beta1.00
S&P 52W Chg18.16%
Avg Vol (30d)171.62K
Avg Vol (10d)119.22K
Technical Indicators
RSI (14)51.3
MACD0.1178
MACD Signal0.1988
MACD Hist.-0.0810
BB Upper44.09 CHF
BB Middle43.90 CHF
BB Lower43.70 CHF
BB Width0.91%
ATR (14)0.5502 CHF
Vol Ratio (20d)0.91x